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Abstract
Background—The US Food and Drug Administration’s meta-analyses of placebo-controlled
antidepressant trials found approximately twice the rate of suicidal behaviors among children and
adults 24 years of age and younger who were randomized to receive antidepressant medication,
compared with those who were randomized to placebo. Rates of suicidal behavior were similar for
subjects 25 to 64 years of age whether they received antidepressants or placebo, and subjects 65
years of age or older randomized to antidepressants were found to have lower rates of suicidal
behavior. Age stratified FDA meta-analyses did not have adequate power to investigate rates of
suicidal behaviors by antidepressant drug class.
Objective—To assess the risk of deliberate self-harm associated with the two most commonly
prescribed classes of antidepressant agents.
Design—Propensity score matched cohort study of incident users of antidepressant agents.
Setting—Population-based health care utilization data of US residents.
Patients—US residents 10 to 64 years of age with a recorded diagnosis of depression who
initiated use of selective serotonin reuptake inhibitors (SSRIs) or serotonin norepinephrine
reuptake inhibitors (SNRIs) between January 1, 1998 and December 31, 2010.
Main Outcome Measures—ICD-9 external cause of injury codes E950.x-E958.x (deliberate
self-harm).
Results—102,647 patients between 10 and 24 years of age and 338,021 patients between 25 and
64 years of age initiated therapy with antidepressants. Among 10–24 year olds, prior to propensity
score matching, 75,675 patients initiated therapy with SSRIs and 5,344 initiated SNRIs. After
matching there were 5,344 SNRI users and 10,688 SSRI users. Among the older cohort, 36,037
SNRI users were match to 72,028 SSRI users (from an unmatched cohort of 225,952 SSRI
initiators). Regardless of age cohort, patients initiating SSRIs and patients initiating SNRIs had
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similar rates of deliberate self-harm. Restriction to patients with no antidepressant use in the past 3
years did not alter our findings.
Conclusions—Our findings of similar rates of deliberate self-harm for depressed patients who
initiate treatment with either an SSRI or an SNRI suggests that physicians who have decided that
their patients would benefit from initiating antidepressant therapy need not weigh differential
suicide risk when deciding which class of antidepressant to prescribe.
1. Introduction
The first suggestion from placebo-controlled trials that some antidepressants might increase
the risk of suicide came from a 2003 report to the Food and Drug Administration (FDA) by
GlaxoSmithKline, the manufacturer of the drug paroxetine (a selective serotonin reuptake
inhibitor [SSRI]). [1] That report documented an increased risk of possible suicide-related
adverse events (SREs) in paroxetine-treated pediatric patients with major depressive
disorder. The FDA subsequently requested that manufacturers of 8 other widely used
antidepressants search for similar evidence in their antidepressant databases of pediatric
trials. The FDA investigation culminated in two of the largest meta-analyses of placebo-
controlled trials of antidepressants ever undertaken, which, taken together found that
children and adults 24 years of age and younger who were randomized to receive
antidepressant medication, compared with those who were randomized to placebo, appear to
have approximately twice the rate of suicidal behaviors. [2] [3] Suicidal behavior event rates
were similar for subjects 25 to 64 years of age whether they received antidepressants or
placebo, and subjects 65 years of age or older randomized to antidepressants were found to
have lower rates of suicidal behavior. [3]
The FDA meta-analyses are the largest efforts ever undertaken to use randomized data to
assess clinically relevant questions about possible suicide risk associated with antidepressant
therapy. Nevertheless, suicide-related outcomes are rare events, even among high-risk
subjects, and the FDA analyses lacked the power to determine whether some antidepressant
classes or agents may be safer than others with respect to suicide risk. Consequently, FDA
advisories warn of an increased risk of suicide after starting any antidepressant, regardless of
class or formulation. There are, however, reasons to believe that antidepressants might differ
in their associated suicide risks, perhaps most markedly across classes of antidepressants
where different mechanisms of action can lead to differences in other adverse
pathophysiological effects linked to suicide risk such as anxiety, difficulty falling asleep,
akathisia, and adverse discontinuation effects, [4–15] the latter being a more likely
consequence of commonly prescribed serotonin-norepinephrine reuptake inhibitor (SNRI)
agents, which have much shorter half-lives, compared with commonly used SSRI agents.
[14]
Consistent with the possibility of differential risk across classes of antidepressants, the 2006
FDA meta-analysis of placebo-controlled pediatric trials reported a stronger effect estimate
for SREs with venlafaxine (the predominant SNRI prescribed today) than for other
antidepressants (most of which were SSRIs), albeit with wide confidence intervals. A
secondary analysis of FDA findings by Smith found that antidepressants with longer half-
lives tended to be associated with lower risk of suicidality. [14] These considerations
notwithstanding, non-randomized studies that have compared suicide risks across
antidepressant agents [16–23] have reported somewhat mixed results, with most, but not all
[19, 24] finding no or limited differences in suicide risk by antidepressant class. The two
studies that found differential risk by antidepressant class did not agree, however, on the
antidepressant class or agent that was associated with higher suicide risk, with one
identifying substantially higher risk among older male patients on SSRIs, compared with
older males on non-SSRI antidepressants (mostly tricyclic agents), [24] and the other
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identifying venlafaxine as consistently associated with higher risk of suicide and suicide
attempts, compared with SSRIs and tricyclic antidepressants. [19]
Since the clinical efficacy of antidepressants does not clearly favor one class of
antidepressants over another [25, 26], identifying whether suicide-related risk varies across
antidepressants could be of immediate clinical relevance. The current study, the largest US
cohort study to include children and adults to investigate this question, examines the risk of
Deliberate self-harm among new initiators of SSRIs and SNRIs. The size of our population
of new users of antidepressants (over 300,000 of whom initiate use of SSRIs or SNRIs over
the study period) and the inclusion of more recent data than prior work has the advantage of
conferring greater power to detect differences, if they exist, between the two most widely
prescribed classes of antidepressants today: the SSRIs and the SNRIs. The power to
discriminate between these two classes of antidepressants is not a trivial advantage as type II
error is more likely with smaller studies and is especially important in guiding clinical
judgment based on null findings. [27]
2. Methods
2.1 Patients and data source
The current cohort study involves US patients 10 to 64 years of age with a recorded
diagnosis of depression who initiated use of selective serotonin reuptake inhibitors (SSRIs)
or serotonin norepinephrine reuptake inhibitors (SNRIs) between January 1, 1998 and
December 31, 2010. Initiation was defined as filling an SSRI or SNRI antidepressant
prescription without evidence of having filled a prescription for any class of antidepressants
in the preceding 12 months. Such initiators are referred to throughout as “new users”.
Primary analyses focused on the first treatment episode initiated during the study period.
Eligibility required evidence of depression as indicated by a diagnosis of depression
(International Classification of Diseases, Ninth Revision (ICD-9) codes 296.2x, 296.3x,
298.0x, 300.4x, 309.0x, 309.1x, 311.xx, 293.83, 296.90, 309.28) recorded during the year
prior to antidepressant initiation. Subjects were required to be actively enrolled in a health
plan with prescription benefits that contributed data to our claims database (see below)
during the 15 months prior to initiation (i.e., 12 months for baseline covariate assessment
and an additional 3 months to allow uniform assessment of all patients based on a 60 day
grace period and a usual antidepressant supply of 30 days).
The PharMetrics Claims Database used in this study was purchased from IMS Health and is
comprised of commercial health plan information obtained from managed care plans
throughout the United States. The database includes medical and pharmaceutical claims for
over 61 million unique patients from over 98 health plans (approximately 16 million covered
lives per year). The database includes inpatient and outpatient diagnoses (in ICD-9-CM
format) and procedures (in Current Procedural Terminology (CPT) and Healthcare Common
Procedure Coding System (HCPCS) formats), as well as both retail and mail order records
of all reimbursed dispensed prescriptions. Available data on prescriptions include the
National Drug Code (NDC) as well as the quantity, number of days supplied, and the date of
dispensing. Additional data elements include demographic variables (age, gender,
geographic region), provider specialty, and start and stop dates of health-plan enrollment.
Only health plans that submit data for all members are included in the database. Records in
the PharMetrics database are generally representative of the national, commercially insured
(non-Medicaid/Medicare) population in terms of age and gender. Our analyses focus on
persons 64 years of age and younger, the age-group for which our data are nationally
representative and for which we had sufficient sample size to examine the relation between
antidepressant drug class and deliberate self-harm.
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2.2 Antidepressant medication exposure
Antidepressant medications were classified as SSRIs or SNRIs. SSRIs included citalopram
hydrobromide, fluoxetine hydrochloride, fluvoxamine maleate, paroxetine hydrochloride,
and sertraline hydrochloride; SNRIs included venlafaxine and Duloxetine hydrochloride.
We did not examine tricyclic antidepressants or monoamine oxidase inhibitors given their
infrequent use. Bupropion (Wellbutrin) was excluded from analysis due to its frequent use
for smoking cessation. Patients initiating more than one antidepressant agent on the same
day were excluded.
2.3 Follow-up and study end point
Exposure status was assigned based on the initiated medication. Study follow-up began on
the day after initiation of the first antidepressant therapy. For each patient we created a
record of drug coverage by listing consecutive prescription fills, based on dispensing dates
and reported days supply. When a dispensing occurred before the previous prescription
should have run out, use of the new prescription is assumed to begin the day after the end of
the old prescription. Since users of any prescription medicine, especially chronic users, may
experience relatively brief episodes without a supply of medicine or may skip taking the
medicine some days, our primary analyses allowed for up to 60 extra days to elapse beyond
the provided days supply before censoring (i.e., we use a 60 day grace period, twice the
most common days supply).
Patients were also censored at the date they switched agents (including when switching
occurred within antidepressant class), added other antidepressant agents to the initiated
regimen (i.e., treatment augmentation), 360 days after the index date, ended enrollment in
their health insurance plan, or the end of the study period, whichever came first. New users
were not allowed to become new users again; patients who were prevalent users at the start
of their enrollment were allowed to become new users later during the study period.
The occurrence of deliberate self-harm (DSH) at least one day after initiating antidepressant
therapy was our outcome of interest. Deliberate self-harm was defined as a medical claim
with an International Classification of Diseases, Ninth Revision (ICD-9) external cause of
injury code (E-code) of deliberate self-harm (E950.x-E958.x).
2.4 Patient characteristics
Patient characteristics assessed included age, sex, and several indicators of past year medical
comorbidity including the number of acute hospitalizations for non-psychiatric reasons,
constituents of the Charlson Comorbidity Index score, number of distinct generic drugs
filled, and number of outpatient visits. Psychiatric risk factors included the number of acute
psychiatric hospitalizations, the number of acute hospitalizations for substance abuse,
psychiatric comorbidity, and prior DSH. All patients had at least one depression diagnosis in
the year prior to their index date. A hierarchy of depression severity was constructed for
each patient as a function of the proximity of the most recent depression diagnosis to
antidepressant initiation (i.e., within 30 days of antidepressant initiation vs. within 31–360
days of initiation) and whether the diagnosis was an inpatient or outpatient diagnosis. For
inpatient diagnoses, depression diagnosis was further characterized as to whether the
diagnosis was the primary or secondary diagnosis of record. For outpatient diagnoses,
persons with a single depression diagnosis were distinguished from those with multiple
depression diagnoses in the year prior to initiation of antidepressant therapy. Other
psychiatric disorders were defined as the presence of at least one inpatient or outpatient
diagnosis. These included anxiety or sleep disorders, substance abuse, psychotic disorder,
ADHD, cognitive impairment or dementia, and personality disorder. In addition to
psychiatric comorbidities, we measured a number of general medical comorbidities,
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including malignant neoplasms, opiate use, stroke and transient ischemic attack, Parkinson
disease, seizure disorders, urinary incontinence, cardiovascular disease, and chronic lung
disease. Patients with past year mania, bipolar disorder, or schizophrenic disorder were
excluded from analyses.
2.5 Statistical analyses
We first stratified patients into two age groups, those 10–24 years of age and those 25–64
years of age, guided by the age-related risk of suicidal behavior identified in the FDA’s
meta-analyses of placebo-controlled antidepressant trials. [3] We then estimated propensity
scores for treatment initation of SSRIs vs. SNRIs based on the patient characteristics
described above. Propensity scores were estimated separately for our younger and older age
groups. Up to two patients initiated on SSRI therapy were matched to every patient initiated
on SNRI therapy based on the propensity score using an adaptation of a published algorithm
[Parsons]. [28]. As we selected SSRI patients who most closely matched the less numerous
SNRI patients, the research question we address is what would have happened, with respect
to future Deliberate self-harm, if people who were treated with SNRIs had instead been
treated with SSRI therapy (i.e., effect in the treated rather than in everybody). Since the only
antidepressants that have been approved for treatment of depression in children are an SSRIs
(fluoxetine, escitalopram), our matching algorithm has the added benefit of asking a more
germane clinical question than had our reference population been SSRI users.
Crude DSH rates were calculated for patients exposed to SSRI vs. SNRI antidepressants
over the entire exposure period. After examination of Kaplan-Meier (KM) plots of the
matched cohorts, crude rates were also reported for three time periods: the first 30, 31–90,
and 91–360 days after initiating therapy. Exact methods were used to calculate 95%
confidence intervals. Poisson regression was used to estimate the 90-day risk difference and
Cox proportional hazards regression was used to estimate the 1-year hazard ratio of
antidepressant class on DSH.
Sensitivity analyses examined how robust our findings were to a range of grace periods (7,
14, 30, 90, 180 and 360 days) and to analyses that focused on the first treatment carried
forward (FTCF), the latter meaning that changes in antidepressant exposure do not result in
censoring and, as such, are analogous to “as randomized” analyses in randomized controlled
trials. Additional subgroup analyses restricted subjects to those without a prior DSH, and to
those who had not received antidepressants in the 3 years prior to their index date. We also
plotted Kaplan-Meier curves for DSH–free survival as a function of the duration of
continuous use of the index antidepressant for up to one year.
3. Results
Between January 1, 1998 and December 31, 2010, 102,647 patients between 10 and 24 years
of age with baseline depression and 338,021 patients between 25 and 64 years of age with
baseline depression initiated therapy with antidepressants. Of these, 70% initiated SSRIs
(76.4% of the younger age group; 68.1% of the older), 10% SNRIs (5.5% of younger, 11.0%
of older), 3% tri-or tetracyclic antidepressants (2.2% younger; 3.1% older), and 17% with
other antidepressants (15.9% younger, 17.7% older). Sertraline constituted 25% of all SSRI
initiation, followed by 22% Citalopram, 21% Escitalopram, 20% Fluoxetine, 12%
Paroxetine and few Fluvoxamine initiators. The breakdown of SSRI initiation in the younger
(older) age group was: 28% (25%) Sertraline, 27% (17%) Fluoxetine, 19% (23%)
Citalopram, 16% (22%) Escitalopram, and 9.5% (12%) Paroxetine. Among those initiating
SNRIs, 66% (73% of younger; 65% of older) initiated with Venlafaxine; the remaining
initiated with Duloxetine.
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As shown in Table 1, age-group stratified propensity score matched cohorts of SSRI vs.
SNRI users were balanced across most baseline covariates, including measures of
psychiatric burden. Medical comorbidity was very infrequent among the younger cohorts;
among the older cohorts the frequency of medical disorders was evenly distributed across
drug class categories.
Among our younger cohort, deliberate self-harm events were identified within one year of
initiating antidepressant therapy for 66 patients on SSRIs and 39 patients on SNRIs. Among
our 25–64 year old age group, 81 subjects initiating an SSRI and 49 initiating SNRI
subsequently had a DSH event over the first year of follow-up. Corresponding DSH rates for
10–24 year olds over the first year were 15.3 DSH events per 1000 person-years (95%
confidence interval [CI]: 12.0–19.4) for SSRI users and 17.6 DSH events per 1000 person
years for SNRI users (95% confidence interval [CI]: 12.7–23.8) (Table 2). Rates were
highest over the first 30 days after initiation and declined further with time from the index
date. Rates of DSH among adults 25–64 years of age were similar by class of antidepressant,
but considerably lower than among our younger cohort (with event rates of, respectively, 2.5
and 2.8 per 1000 person-years for the older SSRI and SNRI cohorts (Table 2). For all
cohorts, although the hazards were proportional throughout the 1-year follow-up period,
approximately two-thirds of the DSH events that occurred over the first year of therapy
occurred within the first 3 months (Table 2, Fig 1).
DSH hazard ratios were similar across antidepressant classes, both in younger patents and
older patients (Table 3). Indeed, hazard ratios were very close to one in all sensitivity
analyses. Hazards ratios also differed little when we varied the grace period from 7 days to
360 days and in first dose carried forward analyses.
4. Discussion
We observed little variation in the risk of DSH between classes of antidepressants among
patients aged 10 to 64 years who initiated SNRI or SSRI therapy. Most events occurred in
the first 3 months after treatment initiation. Our results are consistent with the findings of
most other recent observational studies that reported either no evidence of differential risk
across antidepressant classes or agents, or small and inconsistent differences [16–23], as
well as with albeit underpowered findings from meta-analyses of randomized controlled
trials. [29–31]
In contrast to a case control study of older Ontario residents (aged 66 years and older) [24]
we did not observe an increased risk of suicidal acts among SSRI initiators relative to
initiators of other antidepressants in our two cohorts, either in the first month of new use or
thereafter, nor did we find any effect measure modification by age. The Canadian study
reported that SSRIs were associated with a nearly 5-fold increased risk of suicide, compared
with other antidepressants, but the risk appeared to be restricted to males and to the first
month of treatment only. Our findings are also at odds with those from a large cohort study
from the United Kingdom, which found higher risk of suicide and DSH among users of
venlafaxine, compared with users of SSRIs and tricyclics. [19] In this UK study, venlafaxine
users had a markedly higher burden of suicide risk factors at baseline than did users of
SSRIs or tricyclics, including prior use of antidepressants (i.e. the UK study included
prevalent users), and adjustment for measured confounders resulted in a substantial
reduction in the risk estimates, suggesting, as noted by the authors, that residual
confounding may have explained all or much of the observed risk.
Our decision to restrict analyses to new initiators of antidepressants with documented
diagnoses of depression confers several advantages over designs that include prevalent
users, chief among which are the ability to detect adverse events that follow soon after a
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drug is started, assess risks over time, and control for selection bias with baseline patient
characteristics that are not in uenced by effects of antidepressant treatment. In addition
incident user designs also mitigate potential selection bias due to past drug-related history
that might affect current treatment assignment. Because we were interested in adverse
outcomes, our primary analytic strategy was to censor people at the time of treatment
changes. Our decision to censor data for subjects at treatment discontinuation and to use a
proportional-hazards analysis adjusts for differences in treatment persistence. By censoring
patient follow-up as soon as a patient switched drugs, augmented therapy with a different
agent, or changed dose we avoided the problematic comparison of patients who escalate
dose or otherwise change treatment in response to adverse effects, refractory depression, or
worsening symptoms, any of which might be indications of elevated suicide risk, with
patients who do not.
The current study is subject to several potential limitations. First, because we used
administrative data our ability to adjust for the severity of psychiatric illness, as well as
other potential confounders was more limited than had we used more detailed clinical data.
We do, however, adjust for documented psychiatric comorbidity and co-medication, and for
a construct that proxies depression severity by specifying whether a patient’s depression
diagnosis occurred during an inpatient admission for depression, whether the diagnosis was
a primary or secondary diagnosis, and whether the diagnosis occurred within the month
prior to their index date or more remotely. Second, we had no direct measure of
antidepressant adherence, only of whether and when patients filled their prescriptions. Using
prescription data may, however, more accurately measure use than previous studies that
relied on data from self-report surveys. Automated pharmacy records are a good source of
medication data because these records are not subject to information bias [32–34] and they
cover the complete history of drug use, rather than a few time intervals, as is often the case
in self-report literature. In addition, automated drug use records have generally been found
to have concordance of better than 90% with patient self-reports of medication use. [34] In
the case of our null findings, we cannot, however, rule out a small class-related effect that
was obscured by such residual misclassification.
Third, we define drug exposure in our primary analysis in a way that seeks to capture how
patients fill their medications (i.e. analyses are “as treated”), but in so doing admit possible
selection bias due to censoring. [35] That we observed no material differences in DSH risk
across antidepressant class both immediately after initiating therapy and in the latter part of
the follow-up period suggests that the null finding we observed is unlikely to be entirely
attributable to such a censoring-related bias to the null. Fourth, our findings most directly
apply to patients 10–64 years of age initiating therapy with either SSRIs or SNRIs. The
applicability of our findings to patients 65 years of age and older or to other classes of
antidepressant medication is not known. And fifth, although propensity score matching
appears to have balanced measured confounders well, it does not guarantee that the SSRI
and SNRI cohorts are matched on unmeasured confounders.
5. Conclusions
Our study examines whether the risk of DSH differs across the two most commonly
prescribed antidepressant drug classes, not whether prescribing antidepressants for persons
with depression is advisable or not. Our findings of similar DSH rates for depressed patients
who initiate treatment with either an SSRI or an SNRI suggests that physicians who have
decided that their patients would benefit from initiating antidepressant therapy need not
weigh differential suicide risk when deciding which to class of antidepressant to prescribe.
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Table 1a
Baseline characteristics of patients with depression, ages 10–24 years, initiating antidepressant therapy before
and after propensity score matching on the probability of receiving SNRI therapy











 10–15 18,151 (24.0%) 557 (10.4%) 1,214 (11.4%) 557 (10.4%)
 16–19 33,385 (44.1%) 2,083 (39.0%) 4,240 (39.7%) 2,083 (39.0%)
 20–24 24,139 (31.9%) 2,704 (50.6%) 5,234 (49.0%) 2,704 (50.6%)
Sex, M 26,393 (34.9%) 1,883 (35.2%) 3,830 (35.8%) 1,883 (35.2%)
Severity Level of Depression Diagnosis
 T1: Primary Inpatient diagnosis <=30 Days Pre-Index Date 3,043 (4.0%) 246 (4.6%) 545 (5.1%) 246 (4.6%)
 T2: Primary Inpatient diagnosis 31–360 Days Pre-Index Date 520 (0.7%) 48 (0.9%) 108 (1.0%) 48 (0.9%)
 T3: Non-Primary Inpatient diagnosis <=360 Days Pre-Index
Date
1,575 (2.1%) 128 (2.4%) 234 (2.2%) 128 (2.4%)
 T4: 2+ Outpatient diagnosis <=360 Days Pre-Index Date 43,060 (56.9%) 3,233 (60.5%) 5,908 (55.3%) 3,233 (60.5%)
 T5: 1 Outpatient diagnosis <=360 Days Pre-Index Date 27,477 (36.3%) 1,689 (31.6%) 3,893 (36.4%) 1,689 (31.6%)
Anxiety Disorders 18,003 (23.8%) 1,444 (27.0%) 3,106 (29.1%) 1,444 (27.0%)
Baseline DSH 1,005 (1.3%) 63 (1.2%) 146 (1.4%) 63 (1.2%)
Primary Inpatient Depression Diagnosis 3,563 (4.7%) 294 (5.5%) 653 (6.1%) 294 (5.5%)
No Depression diagnosis w/in 30 Days of Index Date 10,891 (14.4%) 1,200 (22.5%) 2,606 (24.4%) 1,200 (22.5%)
Baseline Suicidal Ideation (2006–2010 only) 1,609 (3.5%) 91 (2.9%) 253 (3.8%) 91 (2.9%)
Cognitive Impairment/Dementia 27 (0.0%) 0 (0.0%) 0 0
Personality Disorder 730 (1.0%) 77 (1.4%) 158 (1.5%) 77 (1.4%)
Substance Abuse 6,211 (8.2%) 548 (10.3%) 1,148 (10.7%) 548 (10.3%)
Use of Any Opiate 15,880 (21.0%) 1,374 (25.7%) 2,679 (25.1%) 1,374 (25.7%)
Number of Distinct Drug Prescriptions Filled
 1 (AD Only) 12,202 (16.1%) 807 (15.1%) 1,449 (13.6%) 807 (15.1%)
 2–3 23,189 (30.6%) 1,480 (27.7%) 2,912 (27.2%) 1,480 (27.7%)
 4–5 16,994 (22.5%) 1,110 (20.8%) 2,317 (21.7%) 1,110 (20.8%)
 6–9 16,489 (21.8%) 1,250 (23.4%) 2,615 (24.5%) 1,250 (23.4%)
 10+ 6,801 (9.0%) 697 (13.0%) 1,395 (13.1%) 697 (13.0%)
Number of Psychiatric Hospitalizations, 1+ 3,715 (4.9%) 309 (5.8%) 682 (6.4%) 309 (5.8%)
Number of Outpatient Visits
 <5 15,774 (20.8%) 1,068 (20.0%) 1,952 (18.3%) 1,068 (20.0%)
 5–9 21,931 (29.0%) 1,437 (26.9%) 3,022 (28.3%) 1,437 (26.9%)
 10–19 23,506 (31.1%) 1,612 (30.2%) 3,180 (29.8%) 1,612 (30.2%)
 20–39 11,851 (15.7%) 967 (18.1%) 1,981 (18.5%) 967 (18.1%)
 40+ 2,613 (3.5%) 260 (4.9%) 553 (5.2%) 260 (4.9%)
Number of Hospitalizations for Substance Abuse, 1+ 419 (0.6%) 55 (1.0%) 114 (1.1%) 55 (1.0%)
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Number of Hospitalizations for Other Reasons, 1+ 4,753 (6.3%) 358 (6.7%) 743 (7.0%) 358 (6.7%)
Colorectal Cancer 10 (0.0%) 2 (0.0%) 3 (0.0%) 2 (0.0%)
Prostate Cancer 1 (0.0%) 0 (0.0%)
Other Malignant Neoplasm Cancer 396 (0.5%) 43 (0.8%) 81 (0.8%) 43 (0.8%)
Congestive Heart Failure 63 (0.1%) 7 (0.1%) 13 (0.1%) 7 (0.1%)
Arthritis 166 (0.2%) 17 (0.3%) 27 (0.3%) 17 (0.3%)
Cerebrovascular Disease 190 (0.3%) 27 (0.5%) 55 (0.5%) 27 (0.5%)
Cluster Headaches/Migraines 2,684 (3.5%) 256 (4.8%) 520 (4.9%) 256 (4.8%)
Diabetes 897 (1.2%) 75 (1.4%) 166 (1.6%) 75 (1.4%)
Disorders of the Eye 43 (0.1%) 4 (0.1%) 10 (0.1%) 4 (0.1%)
Gait or Balance Disorder 286 (0.4%) 27 (0.5%) 55 (0.5%) 27 (0.5%)
Hyperparathyroidism 8 (0.0%) 1 (0.0%) 0 (0.0%) 1 (0.0%)
Osteoarthritis 284 (0.4%) 32 (0.6%) 66 (0.6%) 32 (0.6%)
Osteoporosis 39 (0.1%) 8 (0.1%) 14 (0.1%) 8 (0.1%)
Parkinsons Disease 4 (0.0%) 1 (0.0%) 1 (0.0%) 1 (0.0%)
Seizures 558 (0.7%) 43 (0.8%) 110 (1.0%) 43 (0.8%)
Urinary Incontinence 415 (0.5%) 22 (0.4%) 58 (0.5%) 22 (0.4%)













Miller et al. Page 13
Table 1b
Baseline characteristics of patients with depression, ages 25–64 years, initiating antidepressant therapy before
and after propensity score matching on the probability of receiving SNRI therapy











 25–40 93,806 (41.5%) 13,227 (36.7%) 26,992 (37.5%) 13,227 (36.7%)
 41–55 96,389 (42.7%) 16,712 (46.4%) 32,307 (44.9%) 16,712 (46.4%)
 56+ 35,757 (15.8%) 6,098 (16.9%) 12,729 (17.7%) 6,098 (16.9%)
Sex, M 74,212 (32.8%) 11,202 (31.1%) 23,001 (31.9%) 11,202 (31.1%)
Severity Level of Depression Diagnosis
 T1: Primary Inpatient diagnosis <=30 Days Pre-Index Date 2,150 (1.0%) 450 (1.2%) 928 (1.3%) 450 (1.2%)
 T2: Primary Inpatient diagnosis 31–360 Days Pre-Index Date 406 (0.2%) 142 (0.4%) 235 (0.3%) 142 (0.4%)
 T3: Non-Primary Inpatient diagnosis <=360 Days Pre-Index
Date
5,518 (2.4%) 1,064 (3.0%) 2,016 (2.8%) 1,064 (3.0%)
 T4: 2+ Outpatient Diagnosis <=360 Days Pre-Index Date 116,171 (51.4%) 20,737 (57.5%) 37,969 (52.7%) 20,737 (57.5%)
 T5: 1 Outpatient Diagnosis <=360 Days Pre-Index Date 101,707 (45.0%) 13,644 (37.9%) 30,880 (42.9%) 13,644 (37.9%)
Anxiety Disorders 54,993 (24.3%) 9,402 (26.1%) 19,517 (27.1%) 9,402 (26.1%)
Baseline DSH 519 (0.2%) 93 (0.3%) 185 (0.3%) 93 (0.3%)
Primary Inpatient Depression Diagnosis 2,556 (1.1%) 592 (1.6%) 1,163 (1.6%) 592 (1.6%)
No Depression Diagnosis w/in 3 0 Days of Index Date 45,707 (20.2%) 10,522 (29.2%) 21,068 (29.2%) 10,522 (29.2%)
Baseline Suicidal Ideation (2006–2010 only) 1,103 (0.8%) 218 (0.9%) 463 (1.0%) 218 (0.9%)
Cognitive Impairment/Dementia 242 (0.1%) 47 (0.1%) 95 (0.1%) 47 (0.1%)
Personality Disorder 1,269 (0.6%) 257 (0.7%) 554 (0.8%) 257 (0.7%)
Substance Abuse 20,334 (9.0%) 3,630 (10.1%) 7,853 (10.9%) 3,630 (10.1%)
Use of Any Opiate 72,807 (32.2%) 13,668 (37.9%) 27,456 (38.1%) 13,668 (37.9%)
Number of Distinct Drug Prescriptions Filled
 1 (Antidepressant Only) 21,005 (9.3%) 3,229 (9.0%) 6,213 (8.6%) 3,229 (9.0%)
 2–3 51,943 (23.0%) 7,321 (20.3%) 14,564 (20.2%) 7,321 (20.3%)
 4–5 46,441 (20.6%) 6,688 (18.6%) 12,834 (17.8%) 6,688 (18.6%)
 6–9 60,524 (26.8%) 9,556 (26.5%) 19,454 (27.0%) 9,556 (26.5%)
 10+ 46,039 (20.4%) 9,243 (25.6%) 18,963 (26.3%) 9,243 (25.6%)
Number of Psychiatric Hospitalizations, 1+ 2,694 (1.2%) 608 (1.7%) 1,197 (1.7%) 608 (1.7%)
Number of Outpatient Visits
 <5 39,311 (17.4%) 4,966 (13.8%) 9,338 (13.0%) 4,966 (13.8%)
 5–9 54,399 (24.1%) 7,671 (21.3%) 15,001 (20.8%) 7,671 (21.3%)
 10–19 67,688 (30.0%) 10,581 (29.4%) 21,639 (30.0%) 10,581 (29.4%)
 20–39 46,533 (20.6%) 8,436 (23.4%) 17,357 (24.1%) 8,436 (23.4%)
 40+ 18,021 (8.0%) 4,383 (12.2%) 8,693 (12.1%) 4,383 (12.2%)
Number of Hospitalizations for Substance Abuse, 1+ 1,192 (0.5%) 241 (0.7%) 524 (0.7%) 241 (0.7%)
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Number of Hospitalizations for Other Reasons, 1+ 25,038 (11.1%) 4,055 (11.3%) 8,511 (11.8%) 4,055 (11.3%)
Colorectal Cancer 563 (0.2%) 90 (0.2%) 213 (0.3%) 90 (0.2%)
Prostate Cancer 636 (0.3%) 101 (0.3%) 224 (0.3%) 101 (0.3%)
Other Malignant Neoplasm Cancer 7,842 (3.5%) 1,555 (4.3%) 3,325 (4.6%) 1,555 (4.3%)
Congestive Heart Failure 2,477 (1.1%) 449 (1.2%) 938 (1.3%) 449 (1.2%)
Arthritis 2,110 (0.9%) 576 (1.6%) 1,143 (1.6%) 576 (1.6%)
Cerebrovascular Disease 4,777 (2.1%) 875 (2.4%) 1,838 (2.6%) 875 (2.4%)
Cluster Headaches/Migraines 10,188 (4.5%) 2,256 (6.3%) 4,642 (6.4%) 2,256 (6.3%)
Diabetes 17,361 (7.7%) 3,235 (9.0%) 6,737 (9.4%) 3,235 (9.0%)
Disorders of the Eye 285 (0.1%) 49 (0.1%) 105 (0.1%) 49 (0.1%)
Gait or Balance Disorder 2,426 (1.1%) 522 (1.4%) 1,065 (1.5%) 522 (1.4%)
Hyperparathyroidism 325 (0.1%) 80 (0.2%) 159 (0.2%) 80 (0.2%)
Osteoarthritis 14,325 (6.3%) 3,217 (8.9%) 6,528 (9.1%) 3,217 (8.9%)
Osteoporosis 3,776 (1.7%) 863 (2.4%) 1,758 (2.4%) 863 (2.4%)
Parkinson’s Disease 231 (0.1%) 36 (0.1%) 72 (0.1%) 36 (0.1%)
Seizures 1,641 (0.7%) 302 (0.8%) 686 (1.0%) 302 (0.8%)
Urinary Incontinence 2,421 (1.1%) 547 (1.5%) 1,152 (1.6%) 547 (1.5%)
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Table 3
Deliberate self-harm hazard ratios (HR) during 1-year follow-up comparing propensity score matched subjects
initiating SNRI vs. SSRI* antidepressant therapy, by age group
Age 10–24 Age 25–64
Primary analyses (Grace Period=60days) 1.17 (0.79, 1.73) 1.18 (0.83, 1.68)
Grace period 7 days 1.30 (0.79, 2.13) 1.04 (0.67, 1.60)
Grace period 14 days 1.25 (0.79, 1.99) 1.24 (0.83, 1.86)
Grace period 30 days 1.27 (0.84, 1.94) 1.16 (0.80, 1.68)
Grace period 90 days 1.17 (0.80, 1.71) 1.19 (0.84, 1.68)
Grace period 180 days 1.11 (0.77, 1.61) 1.15 (0.82, 1.61)
Grace period 360 days 1.07 (0.74, 1.55) 1.17 (0.84, 1.62)
First dose carried forward 1.07 (0.78, 1.46) 1.04 (0.78, 1.37)
Treatment naïve x 3years 0.86 (0.43, 1.74) 1.30 (0.58, 2.89)
The age-group specific SSRI cohort serves as the reference group for the age-group analyses.
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